Update on treatments for dystonia
D Cristopher Bragg1, Nutan Sharma
1Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Current Neurology and Neuroscience Reports
|April 19, 2014
Summary
This review covers evidence-based treatments for dystonia, including oral medications, botulinum toxin injections, and deep brain stimulation. It highlights recent advances and practical applications for improving patient function and preventing complications.
Area of Science:
- Neurology
- Movement Disorders
Background:
- Dystonia is a neurological movement disorder characterized by involuntary muscle contractions.
- Current treatments include oral medications, botulinum toxin injections, and deep brain stimulation.
- Physical and supportive therapies are crucial for managing complications like contractures and enhancing function.
Purpose of the Study:
- To review evidence-based medical treatments for dystonia.
- To emphasize recent advancements in dystonia therapeutics.
- To discuss the application of current treatment approaches in clinical practice.
Main Methods:
- Literature review of evidence-based medical treatments for dystonia.
- Analysis of recent advances in pharmacological and interventional therapies.
- Discussion of supportive and physical therapy roles.
Main Results:
- Established treatments like oral medications, botulinum toxin, and deep brain stimulation remain central.
- Recent advances offer new possibilities for managing dystonia symptoms.
- Supportive therapies play a vital role in functional improvement and complication prevention.
Conclusions:
- A comprehensive approach integrating medical, interventional, and supportive therapies is essential for optimal dystonia management.
- Individualized treatment plans are key to addressing the diverse needs of dystonia patients.
- Ongoing research into novel therapies promises improved outcomes for individuals with dystonia.
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
2.2K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
2.2K
01:31Skeletal Muscle Relaxants: Therapeutic Uses
1.2K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:12Alterations in Muscle Tone ll
27
Alterations in muscle tone are common manifestations of neurological disorders and reflect dysfunction within different nervous system regions. Spasticity, paratonia, and dystonia represent distinct forms of hypertonia, each with unique mechanisms, clinical features, and diagnostic importance.CharacteristicsSpasticity happens from upper motor neuron lesions and is characterized by velocity-dependent resistance to passive movement. Clinical features include:Exaggerated deep tendon reflexesClonus...
27
01:20Myasthenia Gravis: Overview and Treatment
3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
01:24Centrally Acting Muscle Relaxants: Therapeutic Uses
1.7K
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
1.7K